FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080992385> ?p ?o ?g. }

• W3080992385 endingPage "22" @default.
• W3080992385 startingPage "13" @default.
• W3080992385 abstract "Strategies to improve the early diagnosis of prostate cancer will provide opportunities for earlier intervention. The blood-based prostate-specific antigen (PSA) assay is widely used for prostate cancer diagnosis but specificity of the assay is not satisfactory. An algorithm based on serum levels of PSA combined with other serum biomarkers may significantly improve prostate cancer diagnosis. Plasma glycan-binding IgG/IgM studies suggested that glycan patterns differ between normal and tumor cells. We hypothesize that in prostate cancer glycoproteins or glycolipids are secreted from tumor tissues into the blood and induce auto-immunoglobulin (Ig) production. A 24-glycan microarray and a 5-glycan subarray were developed using plasma samples obtained from 35 prostate cancer patients and 54 healthy subjects to identify glycan-binding auto-IgGs. Neu5Acα2-8Neu5Acα2-8Neu5Acα (G81)-binding auto-IgG was higher in prostate cancer samples and, when levels of G81-binding auto-IgG and growth differentiation factor-15 (GDF-15 or NAG-1) were combined with levels of PSA, the prediction rate of prostate cancer increased from 78.2% to 86.2% than with PSA levels alone. The G81 glycan-binding auto-IgG fraction was isolated from plasma samples using G81 glycan-affinity chromatography and identified by N-terminal sequencing of the 50 kDa heavy chain variable region of the IgG. G81 glycan-binding 25 kDa fibroblast growth factor-1 (FGF1) fragment was also identified by N-terminal sequencing. Our results demonstrated that a multiplex diagnostic combining G81 glycan-binding auto-IgG, GDF-15/NAG-1 and PSA (≥ 2.1 ng PSA/ml for cancer) increased the specificity of prostate cancer diagnosis by 8%. The multiplex assessment could improve the early diagnosis of prostate cancer thereby allowing the prompt delivery of prostate cancer treatment." @default.
• W3080992385 created "2020-09-01" @default.
• W3080992385 creator A5010373417 @default.
• W3080992385 creator A5021272911 @default.
• W3080992385 creator A5024825118 @default.
• W3080992385 creator A5046653458 @default.
• W3080992385 creator A5060476901 @default.
• W3080992385 creator A5078409765 @default.
• W3080992385 creator A5085207736 @default.
• W3080992385 creator A5087780392 @default.
• W3080992385 creator A5091841050 @default.
• W3080992385 date "2020-08-20" @default.
• W3080992385 modified "2023-09-26" @default.
• W3080992385 title "Levels of plasma glycan-binding auto-IgG biomarkers improve the accuracy of prostate cancer diagnosis" @default.
• W3080992385 cites W1757407923 @default.
• W3080992385 cites W1831636259 @default.
• W3080992385 cites W1862930219 @default.
• W3080992385 cites W1964816209 @default.
• W3080992385 cites W1967708173 @default.
• W3080992385 cites W1968196198 @default.
• W3080992385 cites W1987908689 @default.
• W3080992385 cites W1994321217 @default.
• W3080992385 cites W1997829698 @default.
• W3080992385 cites W2003233791 @default.
• W3080992385 cites W2020474446 @default.
• W3080992385 cites W2032499003 @default.
• W3080992385 cites W2041181510 @default.
• W3080992385 cites W2043310037 @default.
• W3080992385 cites W2044780723 @default.
• W3080992385 cites W2100331658 @default.
• W3080992385 cites W2128132557 @default.
• W3080992385 cites W2132226869 @default.
• W3080992385 cites W2134161198 @default.
• W3080992385 cites W2154442758 @default.
• W3080992385 cites W2163376077 @default.
• W3080992385 cites W2250233848 @default.
• W3080992385 cites W2415216200 @default.
• W3080992385 cites W2581104586 @default.
• W3080992385 cites W2629253656 @default.
• W3080992385 cites W2790016557 @default.
• W3080992385 cites W2806299764 @default.
• W3080992385 cites W2883541766 @default.
• W3080992385 cites W2885691629 @default.
• W3080992385 doi "https://doi.org/10.1007/s11010-020-03876-7" @default.
• W3080992385 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7867609" @default.
• W3080992385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32816187" @default.
• W3080992385 hasPublicationYear "2020" @default.
• W3080992385 type Work @default.
• W3080992385 sameAs 3080992385 @default.
• W3080992385 citedByCount "2" @default.
• W3080992385 countsByYear W30809923852023 @default.
• W3080992385 crossrefType "journal-article" @default.
• W3080992385 hasAuthorship W3080992385A5010373417 @default.
• W3080992385 hasAuthorship W3080992385A5021272911 @default.
• W3080992385 hasAuthorship W3080992385A5024825118 @default.
• W3080992385 hasAuthorship W3080992385A5046653458 @default.
• W3080992385 hasAuthorship W3080992385A5060476901 @default.
• W3080992385 hasAuthorship W3080992385A5078409765 @default.
• W3080992385 hasAuthorship W3080992385A5085207736 @default.
• W3080992385 hasAuthorship W3080992385A5087780392 @default.
• W3080992385 hasAuthorship W3080992385A5091841050 @default.
• W3080992385 hasBestOaLocation W30809923852 @default.
• W3080992385 hasConcept C108625454 @default.
• W3080992385 hasConcept C121608353 @default.
• W3080992385 hasConcept C126322002 @default.
• W3080992385 hasConcept C153911025 @default.
• W3080992385 hasConcept C159654299 @default.
• W3080992385 hasConcept C185592680 @default.
• W3080992385 hasConcept C203014093 @default.
• W3080992385 hasConcept C206212055 @default.
• W3080992385 hasConcept C2776235491 @default.
• W3080992385 hasConcept C2780192828 @default.
• W3080992385 hasConcept C2781188995 @default.
• W3080992385 hasConcept C2781406297 @default.
• W3080992385 hasConcept C502942594 @default.
• W3080992385 hasConcept C60644358 @default.
• W3080992385 hasConcept C71924100 @default.
• W3080992385 hasConcept C86803240 @default.
• W3080992385 hasConceptScore W3080992385C108625454 @default.
• W3080992385 hasConceptScore W3080992385C121608353 @default.
• W3080992385 hasConceptScore W3080992385C126322002 @default.
• W3080992385 hasConceptScore W3080992385C153911025 @default.
• W3080992385 hasConceptScore W3080992385C159654299 @default.
• W3080992385 hasConceptScore W3080992385C185592680 @default.
• W3080992385 hasConceptScore W3080992385C203014093 @default.
• W3080992385 hasConceptScore W3080992385C206212055 @default.
• W3080992385 hasConceptScore W3080992385C2776235491 @default.
• W3080992385 hasConceptScore W3080992385C2780192828 @default.
• W3080992385 hasConceptScore W3080992385C2781188995 @default.
• W3080992385 hasConceptScore W3080992385C2781406297 @default.
• W3080992385 hasConceptScore W3080992385C502942594 @default.
• W3080992385 hasConceptScore W3080992385C60644358 @default.
• W3080992385 hasConceptScore W3080992385C71924100 @default.
• W3080992385 hasConceptScore W3080992385C86803240 @default.
• W3080992385 hasFunder F4320337351 @default.
• W3080992385 hasIssue "1" @default.
• W3080992385 hasLocation W30809923851 @default.
• W3080992385 hasLocation W30809923852 @default.

• next